Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

With morale at a low point, biotech and pharma CEOs are cautiously optimistic about the incoming Trump administration.

The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...